General Medicine and Family Physicians and Dietitians who care for patients with binge eating disorder. Other health care providers, including nurse practitioners and physician assistants, may also participate.
Binge Eating Disorder, Eating Disorders, Obesity
1. | Describe the prevalence, burden, and public health impact of BED | 2. | Identify misconceptions, biases, and negative attitudes commonly associated with BED in order to assess how they impact diagnosis, treatment, and communication with your at-risk patients |
3. | Review and assess non-pharmacologic approaches to managing BED | 4. | Compare and contrast pharmacologic approaches to treating BED |
1. | Describe the prevalence, burden, and public health impact of BED |
2. | Identify misconceptions, biases, and negative attitudes commonly associated with BED in order to assess how they impact diagnosis, treatment, and communication with your at-risk patients |
3. | Review and assess non-pharmacologic approaches to managing BED |
4. | Compare and contrast pharmacologic approaches to treating BED |
This educational activity is supported by an independent educational grant from Shire Pharmaceuticals.
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:
Nature of Relationship | Commercial Entity |
Advisory Board/Consultant: | Self: Alkermes, Actavis (Forest Laboratories), Merck, Otsuka, ProPhase, Shire Pharmaceuticals, Supernus, Sunovion Spouse: Shire, Sunovion |
Grant Recipient/Research Support (Funds paid to Lindner Center of HOPE) | Spouse (PI): Actavis (Forest Laboratories), Alkermes, AstraZeneca, GlaxoSmithKline; Lilly; Marriott Foundation; NIMH; Orexigen; Pfizer; Shire Pharmaceuticals, Takeda Pharmaceuticals, Teva Pharmaceutical Industries, Ltd. (Cephalon) |
Intellectual Property Patients | Self (co-inventor): Methods of treating obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual - no financial gain from this patent; Spouse (inventor) Use of sulfamate derivatives for treating impulse control disorders - has received payments from Johnson & Johnson Pharmaceutical Research & Development which has exclusive rights under patent. |
Off-label | Antidepressants (SSRIs; SNRIs; TCAs; NRIs; NDRIs); Anti-obesity agents (orlistat; sibutramine and fenfluramine (both withdrawn from the market); and Antieplielptics (phenytoin, valproate, carbamazepine, lamotrigine, zonisamide, and topiramate) |
Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. |